Dr. Hill is devoted to addressing substance use challenges through community engaged research and innovative educational programs. He serves as Director of the Implementation and Research Center for Healthy Communities (IRC), a team of faculty and staff that improves health and well-being through innovative health services research, robust curriculum development and evaluation, and application of implementation science principles to advance evidence-based practices in healthcare and community settings. Dr. Hill graduated from the University of Missouri–Kansas City School of Pharmacy, completed a family medicine pharmacy residency at UPMC St. Margaret, and completed a faculty development fellowship at the University of Pittsburgh School of Medicine. He founded the PhARM Program at The University of Texas at Austin and led several Texas Targeted Opioid Response projects focused on health professional education and community overdose prevention. Dr. Hill's current research focuses on identifying, exploring, and addressing gaps in pharmacy implementation of evidence-based substance use disorder treatment and harm reduction strategies. He serves on the board of directors of the Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA), the editorial board of the Journal of the American College of Clinical Pharmacy (JACCP), and the National Methadone Access and Quality Commission (NMAQC).
Education & Training
Clinical Pharmacy Residency
University of Pittsburgh Medical Center
Faculty Development Fellowship
University of Pittsburgh School of Medicine
Doctor of Pharmacy
University of Missouri–Kansas City School of Pharmacy
Research Expertise
- Substance Use Disorders
- Harm Reduction Strategies
- Opioid Stewardship Programs
- Clinical Pharmacy Services
- Continuing Professional Development
Highlighted Publications
- Hendy LE, Hill LG, Olguin A, Barrett E, Jimes C, Coffey MJ, Lira MC. (2025). Pharmacy barriers to receiving buprenorphine among patients in telemedicine addiction treatment. JAMA Netw Open. 8(8): e2527418. DOI: 10.1001/jamanetworkopen.2025.27418.
- Loera LJ, Lines J, Mayberry S, Hilzendager S, Ferguson A, Hill LG. (2025). Over-the-counter naloxone and non-prescription syringe availability in community pharmacies. JAMA Netw Open. 8(2):e2458095. DOI: 10.1001/jamanetworkopen.2024.58095.
- Varisco TJ, Fish H, Bolin J, Dadiomov D, Hill LG, Essien E, Wanat MA, Ginsburg D, Waggener J, Thornton D. (2024). The pharmacy access to resources and medication for opioid use disorder (PhARM-OUD) guideline: A joint consensus practice guideline from the National Association of Boards of Pharmacy and the National Community Pharmacists Association. DOI: 10.52713/PhARM-OUD.
- Zagorski CM, Hosey R, Moraff C, Ferguson A, Figgatt M, Aronowitz S, Stahl N, Hill LG, McElligott Z, Dasgupta N. (2023). Reducing the harms of xylazine: Clinical approaches, research deficits, and public health context. Harm Reduct J. 20:141. DOI: 10.1186/s12954-023-00879-7.
- Hill LG, Light AE, Green TC, Burns AL, Sanaty Zadeh P, Freeman PR. (2023). Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists. J Am Pharm Assoc. 63(1):252-260. DOI: 10.1016/j.japh.2022.08.017.
- Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel H, Peckham AM, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR. (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 237:109518. DOI: 10.1016/j.drugalcdep.2022.109518.
- Hill LG, Zagorski CM, Loera LJ. (2022). Increasingly powerful opioid antagonists are not necessary. Int J Drug Policy. 99:103457. DOI: 10.1016/j.drugpo.2021.103457.
- Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. (2021). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 116(6):1505-1511. DOI: 10.1111/ADD.15314.
- Hill LG, Holleran Steiker LK, Mazin L, Kinzly ML. (2020). Implementation of a collaborative model for opioid overdose prevention on campus. J Am Coll Health. 68(3):223-226. DOI: 10.1080/07448481.2018.1549049.
- Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. (2018). Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 320(18):1934-1937. DOI: 10.1001/jama.2018.15892.
- Hill LG, Sanchez JP, Laguado SA, Lawson KA. (2018). Operation Naloxone: Overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 10(10):1348-1353. DOI: 10.1016/j.cptl.2018.07.010.
Highlighted Popular Media
- CNN Newsroom: FDA approves overdose treatment Narcan for over-the-counter use
- TIME: Over-the-counter Narcan is a great first step, but there's still work to be done
- TIME: Fewer than half of U.S. pharmacies carry one of the most effective drugs for opioid abuse
- The Atlantic: An anti-overdose drug is getting stronger. Maybe that’s a bad thing?
- KCRW Los Angeles: Can you OD from touching fentanyl? How that myth gained a foothold among first responders.
- Texas Public Radio: Drug overdoses spiked during the pandemic. What’s fueling the surge?
- VICE News: No, border patrol doesn’t need to be protected from fentanyl
- Washington Post: A myth that lingers on – Casual contact with fentanyl causes overdoses
- Popular Science: The CDC says more prescriptions of overdose reversal drug naloxone are needed
- KCBS San Francisco: Preventing overdose deaths on campus
- NPR All Things Considered: On college campuses, making overdose medication readily available
- Alcalde: How Texas is trying to stay ahead of the opioid epidemic
- NPR Marketplace: Overdose prevention on campus
Honors & Awards
- American College of Clinical Pharmacy: Fellow (2023)
- American College of Clinical Pharmacy: New Educator Award (2021)
- American College of Clinical Pharmacy AmCare PRN: Outstanding Paper of the Year (2021)
- Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2021)
- American Pharmacists Association: Generation Rx Award of Excellence (2020)
- American College of Clinical Pharmacy AmCare PRN: Outstanding Paper of the Year (2019)
- Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2019)
- UT College of Pharmacy: Outstanding Faculty Advisor (2019)
- American Society of Health-System Pharmacists: CEO’s Award for Courageous Service (2018)
- Texas Pharmacy Association: Generation Rx Champion Award (2018)
- UT College of Pharmacy: William Arlyn Kloesel Outstanding APPE Preceptor (2017)
